14 October 2019 in IEEE Reviews in Biomedical Engineering
Reliable brain tumor segmentation is essential for accurate diagnosis and treatment planning. Since manual segmentation of brain tumors is a highly time-consuming, expensive and subjective task, practical automated methods for this purpose are greatly appreciated. But since brain tumors are highly heterogeneous in terms of location, shape, and size, developing automatic segmentation methods has remained a challenging task over decades. This paper aims to review the evolution of automated models for brain tumor segmentation using multimodal MR images. In order to be able to make a just comparison between different methods, the proposed models are studied for the most famous benchmark for brain tumor segmentation, namely the BraTS challenge [1]. The BraTS 2012-2018 challenges and the state-of-the-art automated models employed each year are analysed. The changing trend of these automated methods since 2012 are studied and the main parameters that affect the performance of different models are analysed.
3 April 2014 in Human Brain Mapping
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
+6
4 March 2015 in The Journal of Clinical Pharmacology
Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which covariates influence the disposition of CZP. The final CZP population PK model consisted of a baseline, first-order absorption, and 1-compartment disposition. CZP antibodies were treated as a structural model covariate and caused apparent clearance (CL/F) to increase from 0.685 to 2.74 L/day. Body surface area (BSA) influenced both CL/F and apparent volume of distribution (V/F) in a linear fashion; both parameters increased by more than 53% and 49%, respectively, across the range of BSA measurements in the data. Albumin influenced CZP CL/F in a nonlinear fashion; CL/F decreased from 1.05 to 0.613 L/day with increasing albumin concentrations in antibody-negative patients. C-reactive protein (CRP) had a borderline influence and CL/F increased by more than 20% across the range of CRP measurements in the data set. Race had a minor influence on V/F. The determined covariates' impact on CZP disposition may be of clinical utility in CZP therapy of CD patients when the PK/pharmacodynamic relationship becomes available.
1 February 2022 in Magnetic Resonance Imaging
1 September 2000 in Brain Research Bulletin
KJKathrine Jauregui-Renaud